Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies
Tóm tắt
Từ khóa
Tài liệu tham khảo
Adams, 1998, Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure, Proc Natl Acad Sci U S A, 95, 10140, 10.1073/pnas.95.17.10140
Adams, 2000, Structure and function of the type 1 insulin-like growth factor receptor, Cell Mol Life Sci, 57, 1050, 10.1007/PL00000744
2004
Aikawa, 1999, Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes, Circ Res, 84, 458, 10.1161/01.RES.84.4.458
Akazawa, 2003, Roles of cardiac transcription factors in cardiac hypertrophy, Circ Res, 92, 1079, 10.1161/01.RES.0000072977.86706.23
Akhter, 1998, Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy, Science, 280, 574, 10.1126/science.280.5363.574
Akki, 2008, Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation, Mol Cell Biochem, 311, 215, 10.1007/s11010-008-9711-y
Allard, 1994, Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts, Am J Physiol, 267, H742
Anand, 2004, Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial, Lancet, 364, 347, 10.1016/S0140-6736(04)16723-8
Anderson, 1990, Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase, Nature, 343, 651, 10.1038/343651a0
Antos, 2002, Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo, Proc Natl Acad Sci U S A, 99, 907, 10.1073/pnas.231619298
Anversa, 2002, Myocyte growth and cardiac repair, J Mol Cell Cardiol, 34, 91, 10.1006/jmcc.2001.1506
Aoki, H. and Izumo, S. (2001). Signal transduction of cardiac myocyte hypertrophy. Heart Physiology and Pathology. Sperelakis, N., Kurachi, Y., Terzic, A. and Cohen, M.V. San Diego, Academic Press: 1065–1086.
Aoki, 1998, Angiotensin II activates RhoA in cardiac myocytes: a critical role of RhoA in angiotensin II-induced premyofibril formation, Circ Res, 82, 666, 10.1161/01.RES.82.6.666
Arai, 1995, Endothelin-1 and its binding sites are upregulated in pressure overload cardiac hypertrophy, Am J Physiol, 268, H2084
Arber, 1997, MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure, Cell, 88, 393, 10.1016/S0092-8674(00)81878-4
Aronow, 2001, Divergent transcriptional responses to independent genetic causes of cardiac hypertrophy, Physiol Genomics, 6, 19, 10.1152/physiolgenomics.2001.6.1.19
Babiker, 2002, Estrogenic hormone action in the heart: regulatory network and function, Cardiovasc Res, 53, 709, 10.1016/S0008-6363(01)00526-0
Backs, 2006, Control of cardiac growth by histone acetylation/deacetylation, Circ Res, 98, 15, 10.1161/01.RES.0000197782.21444.8f
Backs, 2006, CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy, J Clin Invest, 116, 1853, 10.1172/JCI27438
Backs, 2009, The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload, Proc Natl Acad Sci U S A, 106, 2342, 10.1073/pnas.0813013106
Badorff, 2002, Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload, J Clin Invest, 109, 373, 10.1172/JCI13779
Baines, 2005, STRESS signaling pathways that modulate cardiac myocyte apoptosis, J Mol Cell Cardiol, 38, 47, 10.1016/j.yjmcc.2004.11.004
Balakumar, 2006, Differential role of rho-kinase in pathological and physiological cardiac hypertrophy in rats, Pharmacology, 78, 91, 10.1159/000095784
Baltas, 1995, The cardiac sarcoplasmic reticulum phospholamban kinase is a distinct delta-CaM kinase isozyme, FEBS Lett, 373, 71, 10.1016/0014-5793(95)00981-E
Barger, 2000, PPAR signaling in the control of cardiac energy metabolism, Trends Cardiovasc Med, 10, 238, 10.1016/S1050-1738(00)00077-3
Barger, 2000, Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth, J Clin Invest, 105, 1723, 10.1172/JCI9056
Barki-Harrington, 2004, Network integration of the adrenergic system in cardiac hypertrophy, Cardiovasc Res, 63, 391, 10.1016/j.cardiores.2004.03.011
Barrans, 2001, Construction of a human cardiovascular cDNA microarray: portrait of the failing heart, Biochem Biophys Res Commun, 280, 964, 10.1006/bbrc.2000.4137
Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5
Bassett, 2003, Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions, Mol Cell Endocrinol, 213, 1, 10.1016/j.mce.2003.10.033
Bassi, 2008, Targeting p38-MAPK in the ischaemic heart: kill or cure?, Curr Opin Pharmacol, 8, 141, 10.1016/j.coph.2008.01.002
Bedotto, 1989, Cardiac hypertrophy induced by thyroid hormone is independent of loading conditions and beta adrenoceptor blockade, J Pharmacol Exp Ther, 248, 632
Bendall, 2002, Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice, Circulation, 105, 293, 10.1161/hc0302.103712
Benjamin, 1989, Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis, Circ Res, 65, 657, 10.1161/01.RES.65.3.657
Berenji, 2005, Does load-induced ventricular hypertrophy progress to systolic heart failure?, Am J Physiol Heart Circ Physiol, 289, H8, 10.1152/ajpheart.01303.2004
Bi, 1999, Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase, J Biol Chem, 274, 10963, 10.1074/jbc.274.16.10963
Bikkina, 1993, Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy, J Am Coll Cardiol, 22, 1111, 10.1016/0735-1097(93)90424-Y
Billet, 2007, Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice, J Clin Invest, 117, 1914, 10.1172/JCI28764
Billet, 2008, Role of angiotensin II AT1 receptor activation in cardiovascular diseases, Kidney Int, 74, 1379, 10.1038/ki.2008.358
Bisognano, 2000, Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice, J Mol Cell Cardiol, 32, 817, 10.1006/jmcc.2000.1123
Bisping, 2006, Gata4 is required for maintenance of postnatal cardiac function and protection from pressure overload-induced heart failure, Proc Natl Acad Sci U S A, 103, 14471, 10.1073/pnas.0602543103
Bleumink, 2004, Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study, Eur Heart J, 25, 1614, 10.1016/j.ehj.2004.06.038
Blinderman, 2008, Symptom distress and quality of life in patients with advanced congestive heart failure, J Pain Sympt Manage, 35, 594, 10.1016/j.jpainsymman.2007.06.007
Boengler, 2008, The myocardial JAK/STAT pathway: from protection to failure, Pharmacol Ther, 120, 172, 10.1016/j.pharmthera.2008.08.002
Bogoyevitch, 1996, Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion, Circ Res, 79, 162, 10.1161/01.RES.79.2.162
Boluyt, 2006, Changes in the rat heart proteome induced by exercise training: increased abundance of heat shock protein hsp20, Proteomics, 6, 3154, 10.1002/pmic.200401356
Bossuyt, 2008, Ca2+/calmodulin-dependent protein kinase IIdelta and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure, Circ Res, 102, 695, 10.1161/CIRCRESAHA.107.169755
Boulton, 1991, ERKs: a family of protein–serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF, Cell, 65, 663, 10.1016/0092-8674(91)90098-J
Bourdoncle, 2005, The nuclear receptor coactivator PGC-1alpha exhibits modes of interaction with the estrogen receptor distinct from those of SRC-1, J Mol Biol, 347, 921, 10.1016/j.jmb.2005.01.048
Bowman, 1997, Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates, J Clin Invest, 100, 2189, 10.1172/JCI119755
Boya, 2005, Inhibition of macroautophagy triggers apoptosis, Mol Cell Biol, 25, 1025, 10.1128/MCB.25.3.1025-1040.2005
Brancaccio, 2003, Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload, Nat Med, 9, 68, 10.1038/nm805
Braz, 2002, PKC alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (ERK1/2), J Cell Biol, 156, 905, 10.1083/jcb.200108062
Braz, 2003, Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling, J Clin Invest, 111, 1475, 10.1172/JCI200317295
Braz, 2004, PKC-alpha regulates cardiac contractility and propensity toward heart failure, Nat Med, 10, 248, 10.1038/nm1000
Bristow, 2000, Beta-adrenergic receptor blockade in chronic heart failure, Circulation, 101, 558, 10.1161/01.CIR.101.5.558
Bristow, 2003, Antiadrenergic therapy of chronic heart failure: surprises and new opportunities, Circulation, 107, 1100, 10.1161/01.CIR.0000054530.87613.36
Bristow, 1982, Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts, N Engl J Med, 307, 205, 10.1056/NEJM198207223070401
Brooks, 2000, Myocardial fibrosis in transforming growth factor beta(1)heterozygous mice, J Mol Cell Cardiol, 32, 187, 10.1006/jmcc.1999.1065
Brower, 2006, The relationship between myocardial extracellular matrix remodeling and ventricular function, Eur J Cardiothorac Surg, 30, 604, 10.1016/j.ejcts.2006.07.006
Brunner, 2006, Cardiovascular endothelins: essential regulators of cardiovascular homeostasis, Pharmacol Ther, 111, 508, 10.1016/j.pharmthera.2005.11.001
Bueno, 2000, The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice, EMBO J, 19, 6341, 10.1093/emboj/19.23.6341
Bueno, 2002, Impaired cardiac hypertrophic response in Calcineurin Abeta-deficient mice, Proc Natl Acad Sci U S A, 99, 4586, 10.1073/pnas.072647999
Buerger, 2006, Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase, J Card Fail, 12, 392, 10.1016/j.cardfail.2006.03.002
Buitrago, 2005, The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy, Nat Med, 11, 837, 10.1038/nm1272
Burelle, 2004, Regular exercise is associated with a protective metabolic phenotype in the rat heart, Am J Physiol Heart Circ Physiol, 287, H1055, 10.1152/ajpheart.00925.2003
Burniston, 2009, Adaptation of the rat cardiac proteome in response to intensity-controlled endurance exercise, Proteomics, 9, 106, 10.1002/pmic.200800268
Bush, 2009, Targeting histone deacetylases for heart failure, Expert Opin Ther Targets, 13, 767, 10.1517/14728220902939161
Callis, 2009, MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice, J Clin Invest, 119, 2772, 10.1172/JCI36154
Cantley, 2002, The phosphoinositide 3-kinase pathway, Science, 296, 1655, 10.1126/science.296.5573.1655
2001
Carley, 2005, Fatty acid metabolism is enhanced in type 2 diabetic hearts, Biochim Biophys Acta, 1734, 112, 10.1016/j.bbalip.2005.03.005
Carroll, 1992, Sex-associated differences in left ventricular function in aortic stenosis of the elderly, Circulation, 86, 1099, 10.1161/01.CIR.86.4.1099
Catalucci, 2009, MicroRNAs in cardiovascular biology and heart disease, Circ Cardiovasc Genet, 2, 402, 10.1161/CIRCGENETICS.109.857425
Chan, 2006, Tackling the EGFR in pathological tissue remodelling, Pulm Pharmacol Ther, 19, 74, 10.1016/j.pupt.2005.04.005
Chang, 2004, Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development, Mol Cell Biol, 24, 8467, 10.1128/MCB.24.19.8467-8476.2004
Chen, 2001, Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC, Proc Natl Acad Sci U S A, 98, 11114, 10.1073/pnas.191369098
Chesley, 2000, The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3′-kinase, Circ Res, 87, 1172, 10.1161/01.RES.87.12.1172
Chien, 2001, To Cre or not to Cre: the next generation of mouse models of human cardiac diseases, Circ Res, 88, 546, 10.1161/01.RES.88.6.546
Chien, 1991, Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response, FASEB J, 5, 3037, 10.1096/fasebj.5.15.1835945
Chiloeches, 1999, Regulation of Ras.GTP loading and Ras-Raf association in neonatal rat ventricular myocytes by G protein-coupled receptor agonists and phorbol ester. Activation of the extracellular signal-regulated kinase cascade by phorbol ester is mediated by Ras, J Biol Chem, 274, 19762, 10.1074/jbc.274.28.19762
Ching, 1996, Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis, Heart, 75, 363, 10.1136/hrt.75.4.363
Chiu, 2001, A novel mouse model of lipotoxic cardiomyopathy, J Clin Invest, 107, 813, 10.1172/JCI10947
Cho, 2001, Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice, J Biol Chem, 276, 38349, 10.1074/jbc.C100462200
Choukroun, 1998, Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy, J Clin Invest, 102, 1311, 10.1172/JCI3512
Choukroun, 1999, Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases, J Clin Invest, 104, 391, 10.1172/JCI6350
Christe, 1994, Altered glucose and fatty acid oxidation in hearts of the spontaneously hypertensive rat, J Mol Cell Cardiol, 26, 1371, 10.1006/jmcc.1994.1155
Christensen, 1983, Sympathetic nervous activity during exercise, Annu Rev Physiol, 45, 139, 10.1146/annurev.ph.45.030183.001035
Chu, 2004, Phosphoproteome analysis of cardiomyocytes subjected to {beta}-adrenergic stimulation: identification and characterization of a cardiac heat shock protein p20, Circ Res, 94, 184, 10.1161/01.RES.0000107198.90218.21
Clark, 2007, Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease, Pharmacol Ther, 116, 192, 10.1016/j.pharmthera.2007.06.013
Clerk, 1999, Activation of protein kinase cascades in the heart by hypertrophic G protein-coupled receptor agonists, Am J Cardiol, 83, 64H, 10.1016/S0002-9149(99)00261-1
Clerk, 2000, Small guanine nucleotide-binding proteins and myocardial hypertrophy, Circ Res, 86, 1019, 10.1161/01.RES.86.10.1019
Clerk, 2001, Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1, Mol Cell Biol, 21, 1173, 10.1128/MCB.21.4.1173-1184.2001
Clerk, 2006, Peptide growth factors signal differentially through protein kinase C to extracellular signal-regulated kinases in neonatal cardiomyocytes, Cell Signal, 18, 225, 10.1016/j.cellsig.2005.04.005
Coats, 2000, Exercise training in heart failure, Curr Control Trials Cardiovasc Med, 1, 155, 10.1186/CVM-1-3-155
Cohn, 1997, Report of the national heart, lung, and blood institute special emphasis panel on heart failure research, Circulation, 95, 766, 10.1161/01.CIR.95.4.766
Colao, 2008, The GH-IGF-I axis and the cardiovascular system: clinical implications, Clin Endocrinol (Oxf), 69, 347, 10.1111/j.1365-2265.2008.03292.x
Colao, 2001, Growth hormone and the heart, Clin Endocrinol (Oxf), 54, 137, 10.1046/j.1365-2265.2001.01218.x
Colao, 2002, The cardiovascular risk of GH-deficient adolescents, J Clin Endocrinol Metab, 87, 3650, 10.1210/jc.87.8.3650
Condorelli, 2002, Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice, Proc Natl Acad Sci U S A, 99, 12333, 10.1073/pnas.172376399
Cook, 1999, Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease, J Mol Cell Cardiol, 31, 1429, 10.1006/jmcc.1999.0979
Cooper, 1987, Cardiocyte adaptation to chronically altered load, Annu Rev Physiol, 49, 501, 10.1146/annurev.ph.49.030187.002441
Cordes, 2009, MicroRNA regulation of cardiovascular development, Circ Res, 104, 724, 10.1161/CIRCRESAHA.108.192872
Cowie, 2000, Survival of patients with a new diagnosis of heart failure: a population based study, Heart, 83, 505, 10.1136/heart.83.5.505
Crackower, 2002, Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways, Cell, 110, 737, 10.1016/S0092-8674(02)00969-8
D'Angelo, 1997, Transgenic Galphaq overexpression induces cardiac contractile failure in mice, Proc Natl Acad Sci U S A, 94, 8121, 10.1073/pnas.94.15.8121
Danzi, 2002, Thyroid hormone-regulated cardiac gene expression and cardiovascular disease, Thyroid, 12, 467, 10.1089/105072502760143836
Dash, 2003, Differential regulation of p38 mitogen-activated protein kinase mediates gender-dependent catecholamine-induced hypertrophy, Cardiovasc Res, 57, 704, 10.1016/S0008-6363(02)00772-1
Davies, 2001, Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study, Lancet, 358, 439, 10.1016/S0140-6736(01)05620-3
Davila-Roman, 2002, Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy, J Am Coll Cardiol, 40, 271, 10.1016/S0735-1097(02)01967-8
De Acetis, 2005, Cardiac overexpression of melusin protects from dilated cardiomyopathy due to long-standing pressure overload, Circ Res, 96, 1087, 10.1161/01.RES.0000168028.36081.e0
de Gasparo, 1995, Proposed update of angiotensin receptor nomenclature, Hypertension, 25, 924, 10.1161/01.HYP.25.5.924
de Gasparo, 2000, International union of pharmacology. XXIII. The angiotensin II receptors, Pharmacol Rev, 52, 415
de Jager, 2001, Mechanisms of estrogen receptor action in the myocardium. Rapid gene activation via the ERK1/2 pathway and serum response elements, J Biol Chem, 276, 27873, 10.1074/jbc.M010984200
de Simone, 1995, Gender differences in left ventricular growth, Hypertension, 26, 979, 10.1161/01.HYP.26.6.979
De Windt, 2000, Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: an apoptosis-independent model of dilated heart failure, Circ Res, 86, 255, 10.1161/01.RES.86.3.255
De Windt, 2001, Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo, Proc Natl Acad Sci U S A, 98, 3322, 10.1073/pnas.031371998
DeBosch, 2006, Akt2 regulates cardiac metabolism and cardiomyocyte survival, J Biol Chem, 281, 32841, 10.1074/jbc.M513087200
DeBosch, 2006, Akt1 is required for physiological cardiac growth, Circulation, 113, 2097, 10.1161/CIRCULATIONAHA.105.595231
Delaughter, 1999, Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice, FASEB J, 13, 1923, 10.1096/fasebj.13.14.1923
Devereux, 2000, Therapeutic options in minimizing left ventricular hypertrophy, Am Heart J, 139, S9, 10.1067/mhj.2000.102902
Diffee, 2003, Microarray expression analysis of effects of exercise training: increase in atrial MLC-1 in rat ventricles, Am J Physiol Heart Circ Physiol, 284, H830, 10.1152/ajpheart.00761.2002
Dillmann, 2002, Cellular action of thyroid hormone on the heart, Thyroid, 12, 447, 10.1089/105072502760143809
Ding, 2007, Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage, Cardiovasc Res, 76, 269, 10.1016/j.cardiores.2007.06.027
Divakaran, 2008, The emerging role of microRNAs in cardiac remodeling and heart failure, Circ Res, 103, 1072, 10.1161/CIRCRESAHA.108.183087
Donaldson, 2009, Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation, Circ Res, 104, 265, 10.1161/CIRCRESAHA.108.190397
Dorn, 2007, The fuzzy logic of physiological cardiac hypertrophy, Hypertension, 49, 962, 10.1161/HYPERTENSIONAHA.106.079426
Dorn, 2005, Protein kinase cascades in the regulation of cardiac hypertrophy, J Clin Invest, 115, 527, 10.1172/JCI24178
Dorn, 1994, Myosin heavy chain regulation and myocyte contractile depression after LV hypertrophy in aortic-banded mice, Am J Physiol, 267, H400
Dorn, 2003, Phenotyping hypertrophy: eschew obfuscation, Circ Res, 92, 1171, 10.1161/01.RES.0000077012.11088.BC
Douglas, 1995, Gender differences in left ventricle geometry and function in patients undergoing balloon dilatation of the aortic valve for isolated aortic stenosis. NHLBI Balloon Valvuloplasty Registry, Br Heart J, 73, 548, 10.1136/hrt.73.6.548
Douglas, 1998, Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload, J Am Coll Cardiol, 32, 1118, 10.1016/S0735-1097(98)00347-7
Du, 2008, Distinct role of adrenoceptor subtypes in cardiac adaptation to chronic pressure overload, Clin Exp Pharmacol Physiol, 35, 355, 10.1111/j.1440-1681.2007.04871.x
Du, 2006, Sex dimorphism in cardiac pathophysiology: experimental findings, hormonal mechanisms, and molecular mechanisms, Pharmacol Ther, 111, 434, 10.1016/j.pharmthera.2005.10.016
Edman, 1994, Identification and characterization of delta B-CaM kinase and delta C-CaM kinase from rat heart, two new multifunctional Ca2+/calmodulin-dependent protein kinase isoforms, Biochim Biophys Acta, 1221, 89, 10.1016/0167-4889(94)90221-6
Edwards, 2005, Regulation of signal transduction pathways by estrogen and progesterone, Annu Rev Physiol, 67, 335, 10.1146/annurev.physiol.67.040403.120151
Eghbali, 2005, Molecular and functional signature of heart hypertrophy during pregnancy, Circ Res, 96, 1208, 10.1161/01.RES.0000170652.71414.16
Eghbali, 2006, Heart hypertrophy during pregnancy: a better functioning heart?, Trends Cardiovasc Med, 16, 285, 10.1016/j.tcm.2006.07.001
Engelhardt, 1999, Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice, Proc Natl Acad Sci U S A, 96, 7059, 10.1073/pnas.96.12.7059
Esposito, 2001, Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure overload, Circulation, 103, 1453, 10.1161/01.CIR.103.10.1453
Estigoy, 2009, Intercalated discs: multiple proteins perform multiple functions in non-failing and failing human hearts, Biophys Rev, 1, 43, 10.1007/s12551-008-0007-y
Exton, 1985, Mechanisms involved in alpha-adrenergic phenomena, Am J Physiol, 248, E633
Fagard, 1997, Impact of different sports and training on cardiac structure and function, Cardiol Clin, 15, 397, 10.1016/S0733-8651(05)70348-9
Fan, 2005, Hsp20 and its cardioprotection, Trends Cardiovasc Med, 15, 138, 10.1016/j.tcm.2005.05.004
Fan, 2005, A transgenic mouse model of heart failure using inducible Galpha q, J Biol Chem, 280, 40337, 10.1074/jbc.M506810200
Fan, 2006, Small heat-shock protein Hsp20 attenuates {beta}-agonist-mediated cardiac remodeling through apoptosis signal-regulating kinase 1, Circ Res, 99, 1233, 10.1161/01.RES.0000251074.19348.af
Farach-Carson, 2003, Steroid hormone interactions with target cells: cross talk between membrane and nuclear pathways, J Pharmacol Exp Ther, 307, 839, 10.1124/jpet.103.055038
Feldman, 1986, Myocardial mechanics in hyperthyroidism: importance of left ventricular loading conditions, heart rate and contractile state, J Am Coll Cardiol, 7, 967, 10.1016/S0735-1097(86)80213-3
Ferrans, 1984, Cardiac hypertrophy: morphological aspects, 187
Fielitz, 2008, Requirement of protein kinase D1 for pathological cardiac remodeling, Proc Natl Acad Sci U S A, 105, 3059, 10.1073/pnas.0712265105
Finck, 2003, A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content, Proc Natl Acad Sci U S A, 100, 1226, 10.1073/pnas.0336724100
Fiorotto, 2003, Persistent IGF-I overexpression in skeletal muscle transiently enhances DNA accretion and growth, FASEB J, 17, 59, 10.1096/fj.02-0289fje
Fischer, 2007, Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis, Basic Res Cardiol, 102, 279, 10.1007/s00395-007-0658-z
Fischer, 2008, Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects, Br J Pharmacol, 153, S414, 10.1038/bjp.2008.1
Flynn, 2009, Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial, JAMA, 301, 1451, 10.1001/jama.2009.457
Forfar, 1982, Abnormal left ventricular function in hyperthyroidism: evidence for a possible reversible cardiomyopathy, N Engl J Med, 307, 1165, 10.1056/NEJM198211043071901
Frey, 2003, Cardiac hypertrophy: the good, the bad, and the ugly, Annu Rev Physiol, 65, 45, 10.1146/annurev.physiol.65.092101.142243
Frey, 2000, Decoding calcium signals involved in cardiac growth and function, Nat Med, 6, 1221, 10.1038/81321
Friddle, 2000, Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy, Proc Natl Acad Sci U S A, 97, 6745, 10.1073/pnas.100127897
Gabel, 2005, Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury, J Mol Cell Cardiol, 38, 289, 10.1016/j.yjmcc.2004.11.013
Gao, 2003, Sex hormones and cardiomyopathic phenotype induced by cardiac beta 2-adrenergic receptor overexpression, Endocrinology, 144, 4097, 10.1210/en.2002-0214
Garavaglia, 1989, Sex differences in cardiac adaptation to essential hypertension, Eur Heart J, 10, 1110, 10.1093/oxfordjournals.eurheartj.a059434
Garcia-Sainz, 1999, Alpha 1-adrenoceptors: subtypes, signaling, and roles in health and disease, Arch Med Res, 30, 449, 10.1016/S0188-0128(99)00059-7
Gembardt, 2008, Cardiovascular phenotype of mice lacking all three subtypes of angiotensin II receptors, FASEB J, 22, 3068, 10.1096/fj.08-108316
Geng, 1999, Apoptosis of cardiac myocytes in Gsalpha transgenic mice, Circ Res, 84, 34, 10.1161/01.RES.84.1.34
Gertz, 1988, Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments, J Clin Invest, 82, 2017, 10.1172/JCI113822
Goodlin, 2009, Palliative care in congestive heart failure, J Am Coll Cardiol, 54, 386, 10.1016/j.jacc.2009.02.078
Gosselin, 2006, Disparate regulation of signaling proteins after exercise and myocardial infarction, Med Sci Sports Exerc, 38, 455, 10.1249/01.mss.0000205138.02440.79
Gottlieb, 2009, Cardioprotection requires taking out the trash, Basic Res Cardiol, 104, 169, 10.1007/s00395-009-0011-9
Grandi, 1992, Influence of age and sex on left ventricular anatomy and function in normals, Cardiology, 81, 8, 10.1159/000175770
Griffiths-Jones, 2006, miRBase: microRNA sequences, targets and gene nomenclature, Nucleic Acids Res, 34, D140, 10.1093/nar/gkj112
Grossman, 1975, Wall stress and patterns of hypertrophy in the human left ventricle, J Clin Invest, 56, 56, 10.1172/JCI108079
Guerra, 1999, Myocyte death in the failing human heart is gender dependent, Circ Res, 85, 856, 10.1161/01.RES.85.9.856
Gunasinghe, 2004, Myocardial basis for heart failure, 57
Gupta, 2008, HDAC4 and PCAF bind to cardiac sarcomeres and play a role in regulating myofilament contractile activity, J Biol Chem, 283, 10135, 10.1074/jbc.M710277200
Gutkind, 1998, Cell growth control by G protein-coupled receptors: from signal transduction to signal integration, Oncogene, 17, 1331, 10.1038/sj.onc.1202186
Gutkind, 1998, The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades, J Biol Chem, 273, 1839, 10.1074/jbc.273.4.1839
Hahn, 2003, Protein kinase Calpha negatively regulates systolic and diastolic function in pathological hypertrophy, Circ Res, 93, 1111, 10.1161/01.RES.0000105087.79373.17
Hamawaki, 1998, Pressure-overload hypertrophy is unabated in mice devoid of AT1A receptors, Am J Physiol, 274, H868
Haq, 2000, Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy, J Cell Biol, 151, 117, 10.1083/jcb.151.1.117
Haq, 2001, Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure, Circulation, 103, 670, 10.1161/01.CIR.103.5.670
Harada, 1998, Acute pressure overload could induce hypertrophic responses in the heart of angiotensin II type 1a knockout mice, Circ Res, 82, 779, 10.1161/01.RES.82.7.779
Hardt, 2002, Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development, Circ Res, 90, 1055, 10.1161/01.RES.0000018952.70505.F1
Harris, 2004, Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload, Circulation, 110, 718, 10.1161/01.CIR.0000138190.50127.6A
Harrison, 2006, Regulation of cardiac stress signaling by protein kinase d1, Mol Cell Biol, 26, 3875, 10.1128/MCB.26.10.3875-3888.2006
Harwood, 2001, Regulation of GSK-3: a cellular multiprocessor, Cell, 105, 821, 10.1016/S0092-8674(01)00412-3
Haunstetter, 1998, Apoptosis: basic mechanisms and implications for cardiovascular disease, Circ Res, 82, 1111, 10.1161/01.RES.82.11.1111
Hayakawa, 2003, Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice, Circulation, 108, 3036, 10.1161/01.CIR.0000101920.72665.58
Hein, 1995, Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice, Nature, 377, 744, 10.1038/377744a0
Hein, 2000, The role of the cytoskeleton in heart failure, Cardiovasc Res, 45, 273, 10.1016/S0008-6363(99)00268-0
Henderson, 2007, Reversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone, Int J Biol Sci, 3, 385, 10.7150/ijbs.3.385
Hill, 2002, Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function, J Biol Chem, 277, 10251, 10.1074/jbc.M110722200
Hirota, 1999, Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress, Cell, 97, 189, 10.1016/S0092-8674(00)80729-1
Hoch, 1999, Identification and expression of delta-isoforms of the multifunctional Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human myocardium, Circ Res, 84, 713, 10.1161/01.RES.84.6.713
Hoesl, 2008, Tamoxifen-inducible gene deletion in the cardiac conduction system, J Mol Cell Cardiol, 45, 62, 10.1016/j.yjmcc.2008.04.008
Horiuchi, 1993, Cardiac hypertrophy in juvenile visceral steatosis (jvs) mice with systemic carnitine deficiency, FEBS Lett, 326, 267, 10.1016/0014-5793(93)81805-A
Hoshijima, 2006, Mechanical stress–strain sensors embedded in cardiac cytoskeleton: Z disk, titin, and associated structures, Am J Physiol Heart Circ Physiol, 290, H1313, 10.1152/ajpheart.00816.2005
Hoshijima, 1998, The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase, J Biol Chem, 273, 7725, 10.1074/jbc.273.13.7725
Hudlicka, 1996, Postnatal growth of the heart and its blood vessels, J Vasc Res, 33, 266, 10.1159/000159155
Hunt, 2009, 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation, Circulation, 119, e391, 10.1161/CIRCULATIONAHA.109.192065
Hunter, 1999, Signaling pathways for cardiac hypertrophy and failure, N Engl J Med, 341, 1276, 10.1056/NEJM199910213411706
Hunter, 1995, Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice, J Biol Chem, 270, 23173, 10.1074/jbc.270.39.23173
Huynh, 2010, Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy, Diabetes, 59, 1512, 10.2337/db09-1456
Hwang, 2000, Identification of differentially expressed genes in cardiac hypertrophy by analysis of expressed sequence tags, Genomics, 66, 1, 10.1006/geno.2000.6171
Hwang, 2002, Determination of minimum sample size and discriminatory expression patterns in microarray data, Bioinformatics, 18, 1184, 10.1093/bioinformatics/18.9.1184
Hwang, 2002, Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure, Physiol Genomics, 10, 31, 10.1152/physiolgenomics.00122.2001
Ichihara, 2006, Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors, J Mol Cell Cardiol, 41, 318, 10.1016/j.yjmcc.2006.05.013
Ichiki, 1995, Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor, Nature, 377, 748, 10.1038/377748a0
Iemitsu, 2001, Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat, Am J Physiol Regul Integr Comp Physiol, 281, R2029, 10.1152/ajpregu.2001.281.6.R2029
Iemitsu, 2003, Cardiac hypertrophy by hypertension and exercise training exhibits different gene expression of enzymes in energy metabolism, Hypertens Res, 26, 829, 10.1291/hypres.26.829
Ikeda, 2005, Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis, J Biol Chem, 280, 29661, 10.1074/jbc.M411694200
Ikeda, 2007, Altered microRNA expression in human heart disease, Physiol Genomics, 31, 367, 10.1152/physiolgenomics.00144.2007
Ito, 1993, Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes, J Clin Invest, 92, 398, 10.1172/JCI116579
Izumo, 1986, All members of the MHC multigene family respond to thyroid hormone in a highly tissue-specific manner, Science, 231, 597, 10.1126/science.3945800
Izumo, 1987, Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals, J Clin Invest, 79, 970, 10.1172/JCI112908
Izumo, 1988, Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload, Proc Natl Acad Sci U S A, 85, 339, 10.1073/pnas.85.2.339
Jalil, 2006, Attenuation of cardiac hypertrophy in carnitine-deficient juvenile visceral steatosis (JVS) mice achieved by lowering dietary lipid, J Biochem, 139, 263, 10.1093/jb/mvj032
Jankowski, 2005, Pregnancy alters nitric oxide synthase and natriuretic peptide systems in the rat left ventricle, J Endocrinol, 184, 209, 10.1677/joe.1.05702
Jennings, 1995, Mechanisms for reduction of cardiovascular risk by regular exercise, Clin Exp Pharmacol Physiol, 22, 209, 10.1111/j.1440-1681.1995.tb01982.x
Jennings, 1986, The effects of changes in physical activity on major cardiovascular risk factors, hemodynamics, sympathetic function, and glucose utilization in man: a controlled study of four levels of activity, Circulation, 73, 30, 10.1161/01.CIR.73.1.30
Jiang, 1997, Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta, J Biol Chem, 272, 30122, 10.1074/jbc.272.48.30122
Jones, 2008, AT2 receptors: functional relevance in cardiovascular disease, Pharmacol Ther, 120, 292, 10.1016/j.pharmthera.2008.08.009
Jopling, 2005, Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA, Science, 309, 1577, 10.1126/science.1113329
Juul, 2002, Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case–control study, Circulation, 106, 939, 10.1161/01.CIR.0000027563.44593.CC
Kadokami, 2000, Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression, J Clin Invest, 106, 589, 10.1172/JCI9307
Kagiyama, 2002, Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense, Circulation, 106, 909, 10.1161/01.CIR.0000030181.63741.56
Kajstura, 2001, IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress, Diabetes, 50, 1414, 10.2337/diabetes.50.6.1414
Kalra, 2002, Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?, Int J Cardiol, 85, 195, 10.1016/S0167-5273(02)00182-1
Kaluski, 2008, Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension—a multi-center randomized study, Cardiology, 109, 273, 10.1159/000107791
Kamei, 2003, PPARgamma coactivator 1beta/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity, Proc Natl Acad Sci U S A, 100, 12378, 10.1073/pnas.2135217100
Kang, 2000, Apoptosis and heart failure: a critical review of the literature, Circ Res, 86, 1107, 10.1161/01.RES.86.11.1107
Kang, 2002, New insights into the role of apoptosis in cardiovascular disease, Circ J, 66, 1, 10.1253/circj.66.1
Kang, 2004, Alterations in apoptosis regulatory factors during hypertrophy and heart failure, Am J Physiol Heart Circ Physiol, 10.1152/ajpheart.00556.2003
Kankaanpaa, 2006, Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels, J Clin Endocrinol Metab, 91, 4689, 10.1210/jc.2006-0584
Kannel, 2002, The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women, J Gend Specif Med, 5, 27
Kasahara, 2003, Nkx2.5 homeoprotein regulates expression of gap junction protein connexin 43 and sarcomere organization in postnatal cardiomyocytes, J Mol Cell Cardiol, 35, 243, 10.1016/S0022-2828(03)00002-6
Kato, 2009, MicroRNAs and their role in progressive kidney diseases, Clin J Am Soc Nephrol, 4, 1255, 10.2215/CJN.00520109
Kaumann, 2008, The low-affinity site of the beta1-adrenoceptor and its relevance to cardiovascular pharmacology, Pharmacol Ther, 118, 303, 10.1016/j.pharmthera.2008.03.009
Kaumann, 1999, Activation of beta2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure, Circulation, 99, 65, 10.1161/01.CIR.99.1.65
Kedzierski, 2001, Endothelin system: the double-edged sword in health and disease, Annu Rev Pharmacol Toxicol, 41, 851, 10.1146/annurev.pharmtox.41.1.851
Kedzierski, 2003, Cardiomyocyte-specific endothelin A receptor knockout mice have normal cardiac function and an unaltered hypertrophic response to angiotensin II and isoproterenol, Mol Cell Biol, 23, 8226, 10.1128/MCB.23.22.8226-8232.2003
Kelland, 2006, Clinical trials of endothelin antagonists in heart failure: a question of dose?, Exp Biol Med (Maywood), 231, 696
Keller, 1995, Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements, Mol Endocrinol, 9, 794, 10.1210/me.9.7.794
Kenessey, 2006, Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways, J Biol Chem, 10.1074/jbc.M512671200
Kerfant, 2007, PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes, Circ Res, 101, 400, 10.1161/CIRCRESAHA.107.156422
Khan, 2006, Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia, Immunology, 118, 10, 10.1111/j.1365-2567.2006.02336.x
Kim, 2008, The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice, J Clin Invest, 118, 124, 10.1172/JCI33255
Kim, 2008, Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy, Mol Endocrinol, 22, 2531, 10.1210/me.2008-0265
Kingma, 1999, Cardiac adaptation to ischemia–reperfusion injury, Ann NY Acad Sci, 874, 83, 10.1111/j.1749-6632.1999.tb09227.x
Kirchhefer, 1999, Activity of cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts, Cardiovasc Res, 42, 254, 10.1016/S0008-6363(98)00296-X
Kiriazis, 2008, Knockout of beta(1)- and beta(2)-adrenoceptors attenuates pressure overload-induced cardiac hypertrophy and fibrosis, Br J Pharmacol, 153, 684, 10.1038/sj.bjp.0707622
Kirkby, 2008, The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?, Br J Pharmacol, 153, 1105, 10.1038/sj.bjp.0707516
Klee, 1998, Regulation of the calmodulin-stimulated protein phosphatase, calcineurin, J Biol Chem, 273, 13367, 10.1074/jbc.273.22.13367
Knoll, 2003, Cardiac mechanotransduction and implications for heart disease, J Mol Med, 81, 750, 10.1007/s00109-003-0488-x
Koch, 1995, Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor, Science, 268, 1350, 10.1126/science.7761854
Kodama, 1997, Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes, Circ Res, 81, 656, 10.1161/01.RES.81.5.656
Koizumi, 1999, Genetic epidemiology of the carnitine transporter OCTN2 gene in a Japanese population and phenotypic characterization in Japanese pedigrees with primary systemic carnitine deficiency, Hum Mol Genet, 8, 2247, 10.1093/hmg/8.12.2247
Kok, 2009, Regulation of phosphoinositide 3-kinase expression in health and disease, Trends Biochem Sci, 34, 115, 10.1016/j.tibs.2009.01.003
Komuro, 1996, Mechanical stretch activates the stress-activated protein kinases in cardiac myocytes, FASEB J, 10, 631, 10.1096/fasebj.10.5.8621062
Kong, 2005, Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats, Physiol Genomics, 21, 34, 10.1152/physiolgenomics.00226.2004
Konhilas, 2004, Sex modifies exercise and cardiac adaptation in mice, Am J Physiol Heart Circ Physiol, 287, H2768, 10.1152/ajpheart.00292.2004
Konhilas, 2006, Exercise can prevent and reverse the severity of hypertrophic cardiomyopathy, Circ Res, 98, 540, 10.1161/01.RES.0000205766.97556.00
Koonen, 2007, CD36 expression contributes to age-induced cardiomyopathy in mice, Circulation, 116, 2139, 10.1161/CIRCULATIONAHA.107.712901
Kovacic-Milivojevic, 2001, Focal adhesion kinase and p130Cas mediate both sarcomeric organization and activation of genes associated with cardiac myocyte hypertrophy, Mol Biol Cell, 12, 2290, 10.1091/mbc.12.8.2290
Koziris, 1999, Serum levels of total and free IGF-I and IGFBP-3 are increased and maintained in long-term training, J Appl Physiol, 86, 1436, 10.1152/jappl.1999.86.4.1436
Krishnan, 2009, Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy, Cell Metab, 9, 512, 10.1016/j.cmet.2009.05.005
Krumholz, 1993, Sex differences in cardiac adaptation to isolated systolic hypertension, Am J Cardiol, 72, 310, 10.1016/0002-9149(93)90678-6
Krutzfeldt, 2005, Silencing of microRNAs in vivo with ‘antagomirs’, Nature, 438, 685, 10.1038/nature04303
Kunisada, 2000, Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy, Proc Natl Acad Sci U S A, 97, 315, 10.1073/pnas.97.1.315
Kuwajima, 1998, Characteristics of cardiac hypertrophy in the juvenile visceral steatosis mouse with systemic carnitine deficiency, J Mol Cell Cardiol, 30, 773, 10.1006/jmcc.1998.0641
Landmesser, 2005, Chronic heart failure: an overview of conventional treatment versus novel approaches, Nat Clin Pract Cardiovasc Med, 2, 628, 10.1038/ncpcardio0371
Lang, 2001, Lineage analysis in the chicken inner ear shows differences in clonal dispersion for epithelial, neuronal, and mesenchymal cells, Dev Biol, 234, 120, 10.1006/dbio.2001.0248
Laskowski, 2006, Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes, Cardiovasc Res, 72, 112, 10.1016/j.cardiores.2006.07.006
Latronico, 2008, MicroRNA and cardiac pathologies, Physiol Genomics, 34, 239, 10.1152/physiolgenomics.90254.2008
Laufer, 1989, Prevalence of cardiac structural and functional abnormalities in untreated primary hypertension, Hypertension, 13, 151, 10.1161/01.HYP.13.2.151
Laughlin, 2004, The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study, J Clin Endocrinol Metab, 89, 114, 10.1210/jc.2003-030967
Lazar, 1993, Thyroid hormone receptors: multiple forms, multiple possibilities, Endocr Rev, 14, 184
Lebrasseur, 2007, Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension, Hypertension, 50, 489, 10.1161/HYPERTENSIONAHA.107.092403
Lecellier, 2005, A cellular microRNA mediates antiviral defense in human cells, Science, 308, 557, 10.1126/science.1108784
Lee, 1993, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14, Cell, 75, 843, 10.1016/0092-8674(93)90529-Y
Leevers, 1996, The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth, EMBO J, 15, 6584, 10.1002/j.1460-2075.1996.tb01049.x
Lefkowitz, 2000, Catecholamines, cardiac beta-adrenergic receptors, and heart failure, Circulation, 101, 1634, 10.1161/01.CIR.101.14.1634
Lehman, 2002, Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth, Heart Fail Rev, 7, 175, 10.1023/A:1015332726303
Lemke, 2001, Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK alpha is the predominant isoform expressed in human heart, J Mol Cell Cardiol, 33, 1527, 10.1006/jmcc.2001.1415
Levy, 1987, Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study, Am J Cardiol, 59, 956, 10.1016/0002-9149(87)91133-7
Levy, 1990, Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study, N Engl J Med, 322, 1561, 10.1056/NEJM199005313222203
Lewis, 2005, Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets, Cell, 120, 15, 10.1016/j.cell.2004.12.035
Li, 1997, Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy, J Clin Invest, 100, 1991, 10.1172/JCI119730
Li, 1998, Activation of JNK in the remote myocardium after large myocardial infarction in rats, Biochem Biophys Res Commun, 246, 816, 10.1006/bbrc.1998.8662
Li, 1999, Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart, Circ Res, 84, 1007, 10.1161/01.RES.84.9.1007
Li, 2005, Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II, Br J Pharmacol, 145, 432, 10.1038/sj.bjp.0706217
Liang, 2003, c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling, EMBO J, 22, 5079, 10.1093/emboj/cdg474
Liang, 2009, MicroRNA: a new frontier in kidney and blood pressure research, Am J Physiol Ren Physiol, 297, F553, 10.1152/ajprenal.00045.2009
Liao, 2001, The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy, Proc Natl Acad Sci U S A, 98, 12283, 10.1073/pnas.211086598
Lijnen, 1999, Renin–angiotensin system, hypertrophy and gene expression in cardiac myocytes, J Mol Cell Cardiol, 31, 949, 10.1006/jmcc.1999.0934
Lim, 2000, Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy, Circulation, 101, 2431, 10.1161/01.CIR.101.20.2431
Lin, 2010, PI3K(p110alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNAs and mRNAs, Arterioscler Thromb Vasc Biol, 30, 724, 10.1161/ATVBAHA.109.201988
Lind, 2006, Genetic basis of hypertrophic cardiomyopathy, Expert Rev Cardiovasc Ther, 4, 927, 10.1586/14779072.4.6.927
Ling, 2009, Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice, J Clin Invest, 119, 1230, 10.1172/JCI38022
Linz, 2009, The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats, Acta Pharmacol Sin, 30, 935, 10.1038/aps.2009.58
Liu, 2004, The inhibitory effect of trilinolein on norepinephrine-induced beta-myosin heavy chain promoter activity, reactive oxygen species generation, and extracellular signal-regulated kinase phosphorylation in neonatal rat cardiomyocytes, J Biomed Sci, 11, 11
Liu, 2006, Pressure overload induces greater hypertrophy and mortality in female mice with p38alpha MAPK inhibition, J Mol Cell Cardiol, 41, 680, 10.1016/j.yjmcc.2006.07.007
Liu, 2009, Cardiac-specific deletion of mkk4 reveals its role in pathological hypertrophic remodeling but not in physiological cardiac growth, Circ Res, 104, 905, 10.1161/CIRCRESAHA.108.188292
Lloyd-Jones, 2009, Heart Disease and Stroke Statistics—2009 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, 119, 480, 10.1161/CIRCULATIONAHA.108.191259
Lorell, 1999, Role of angiotensin AT1, and AT2 receptors in cardiac hypertrophy and disease, Am J Cardiol, 83, 48H, 10.1016/S0002-9149(99)00258-1
Lorenz, 2009, A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy, Nat Med, 15, 75, 10.1038/nm.1893
Louis, 2001, Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001, Eur J Heart Fail, 3, 381, 10.1016/S1388-9842(01)00149-0
Lu, 2009, Loss of cardiac phosphoinositide 3-kinase p110{alpha} results in contractile dysfunction, Circulation, 120, 318, 10.1161/CIRCULATIONAHA.109.873380
Luczak, 2009, Sex-based cardiac physiology, Ann Rev Physiol, 71, 1, 10.1146/annurev.physiol.010908.163156
Luo, 2005, Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy, Mol Cell Biol, 25, 9491, 10.1128/MCB.25.21.9491-9502.2005
Luscher, 2002, Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT), Circulation, 106, 2666, 10.1161/01.CIR.0000038497.80095.E1
Ma, 1998, Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in a PPARgamma-expressing tissue, J Biol Chem, 273, 30131, 10.1074/jbc.273.46.30131
Maass, 2004, Hypertrophy, fibrosis, and sudden cardiac death in response to pathological stimuli in mice with mutations in cardiac troponin T, Circulation, 110, 2102, 10.1161/01.CIR.0000144460.84795.E3
Mackay, 2001, Localization, anchoring, and functions of protein kinase C isozymes in the heart, J Mol Cell Cardiol, 33, 1301, 10.1006/jmcc.2001.1400
MacLellan, 2000, Genetic dissection of cardiac growth control pathways, Annu Rev Physiol, 62, 289, 10.1146/annurev.physiol.62.1.289
Mahmoodzadeh, 2006, Estrogen receptor alpha up-regulation and redistribution in human heart failure, FASEB J, 20, 926, 10.1096/fj.05-5148com
Manabe, 2002, Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy, Circ Res, 91, 1103, 10.1161/01.RES.0000046452.67724.B8
Mangelsdorf, 1995, The nuclear receptor superfamily: the second decade, Cell, 83, 835, 10.1016/0092-8674(95)90199-X
Margulies, 2004, 41
Maric, 1997, Embryonic and postnatal development of the rat renal interstitium, Anat Embryol (Berl), 195, 503, 10.1007/s004290050070
Maron, 2006, The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death, Circulation, 114, 1633, 10.1161/CIRCULATIONAHA.106.613562
Maron, 1998, Prevalence of sudden cardiac death during competitive sports activities in Minnesota high school athletes, J Am Coll Cardiol, 32, 1881, 10.1016/S0735-1097(98)00491-4
Masaki, 1998, Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects, J Clin Invest, 101, 527, 10.1172/JCI1885
Matsuda, 2008, Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload, Proc Natl Acad Sci U S A, 105, 20900, 10.1073/pnas.0808315106
Matsui, 2005, Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt, J Mol Cell Cardiol, 38, 63, 10.1016/j.yjmcc.2004.11.005
Matsui, 2002, Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart, J Biol Chem, 277, 22896, 10.1074/jbc.M200347200
Mayer, 1995, Novel and uncommon isoforms of the calcium sensing enzyme calcium/calmodulin dependent protein kinase II in heart tissue, Basic Res Cardiol, 90, 372, 10.1007/BF00788498
McGavock, 2006, Adiposity of the heart, revisited, Ann Intern Med, 144, 517, 10.7326/0003-4819-144-7-200604040-00011
McKinsey, 2002, Signaling chromatin to make muscle, Curr Opin Cell Biol, 14, 763, 10.1016/S0955-0674(02)00389-7
McMullen, 2008, Role of insulin-like growth factor 1 and phosphoinositide 3-kinase in a setting of heart disease, Clin Exp Pharmacol Physiol, 35, 349, 10.1111/j.1440-1681.2007.04873.x
McMullen, 2009, Nectin-2: an intercalated disc protein that maintains cardiac function in a setting of pressure overload, Hypertension, 54, 713, 10.1161/HYPERTENSIONAHA.109.137976
McMullen, 2007, PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart, Cell Cycle, 6, 10.4161/cc.6.8.4124
McMullen, 2003, Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy, Proc Natl Acad Sci U S A, 100, 12355, 10.1073/pnas.1934654100
McMullen, 2004, Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload, Circulation, 109, 3050, 10.1161/01.CIR.0000130641.08705.45
McMullen, 2004, The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway, J Biol Chem, 279, 4782, 10.1074/jbc.M310405200
McMullen, 2004, Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy, Mol Cell Biol, 24, 6231, 10.1128/MCB.24.14.6231-6240.2004
McMullen, 2007, Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy, Proc Natl Acad Sci U S A, 104, 612, 10.1073/pnas.0606663104
McMurray, 1993, Evidence of oxidative stress in chronic heart failure in humans, Eur Heart J, 14, 1493, 10.1093/eurheartj/14.11.1493
Mende, 1998, Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways, Proc Natl Acad Sci U S A, 95, 13893, 10.1073/pnas.95.23.13893
Mendelsohn, 2005, Molecular and cellular basis of cardiovascular gender differences, Science, 308, 1583, 10.1126/science.1112062
Mikkola, 2002, Estrogen replacement therapy, atherosclerosis, and vascular function, Cardiovasc Res, 53, 605, 10.1016/S0008-6363(01)00466-7
Minamino, 2002, MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq, Proc Natl Acad Sci U S A, 99, 3866, 10.1073/pnas.062453699
Mirotsou, 2006, Physiological genomics of cardiac disease: quantitative relationships between gene expression and left ventricular hypertrophy, Physiol Genomics, 27, 86, 10.1152/physiolgenomics.00028.2006
Miyata, 1994, Hypertrophic growth of cultured neonatal rat heart cells mediated by type 1 angiotensin II receptor, Am J Physiol, 266, H2443
Miyazaki, 2006, Comparison of gene expression profiling in pressure and volume overload-induced myocardial hypertrophies in rats, Hypertens Res, 29, 10.1291/hypres.29.1029
Modesti, 2000, Early sequence of cardiac adaptations and growth factor formation in pressure- and volume-overload hypertrophy, Am J Physiol Heart Circ Physiol, 279, H976, 10.1152/ajpheart.2000.279.3.H976
Mogi, 2009, New insights into the regulation of angiotensin receptors, Curr Opin Nephrol Hypertens, 18, 138, 10.1097/MNH.0b013e328324f5fa
Molenaar, 2005, Fundamental considerations of beta-adrenoceptor subtypes in human heart failure, Trends Pharmacol Sci, 26, 368, 10.1016/j.tips.2005.05.005
Molkentin, 2001, Cytoplasmic signaling pathways that regulate cardiac hypertrophy, Annu Rev Physiol, 63, 391, 10.1146/annurev.physiol.63.1.391
Molkentin, 1998, A calcineurin-dependent transcriptional pathway for cardiac hypertrophy, Cell, 93, 215, 10.1016/S0092-8674(00)81573-1
Moriarty, 2006, Minireview: estrogen receptor-mediated rapid signaling, Endocrinology, 147, 5557, 10.1210/en.2006-0729
Morimoto, 2008, Sarcomeric proteins and inherited cardiomyopathies, Cardiovasc Res, 77, 659, 10.1093/cvr/cvm084
Morisco, 2000, The Akt-glycogen synthase kinase 3beta pathway regulates transcription of atrial natriuretic factor induced by beta-adrenergic receptor stimulation in cardiac myocytes, J Biol Chem, 275, 14466, 10.1074/jbc.275.19.14466
Morisco, 2001, Glycogen synthase kinase 3beta regulates GATA4 in cardiac myocytes, J Biol Chem, 276, 28586, 10.1074/jbc.M103166200
Morissette, 2006, Myostatin regulates cardiomyocyte growth through modulation of Akt signaling, Circ Res, 99, 15, 10.1161/01.RES.0000231290.45676.d4
Morkin, 2000, Control of cardiac myosin heavy chain gene expression, Microsc Res Tech, 50, 522, 10.1002/1097-0029(20000915)50:6<522::AID-JEMT9>3.0.CO;2-U
Murdoch, 2006, NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure, Cardiovasc Res, 71, 208, 10.1016/j.cardiores.2006.03.016
Muslin, 2008, MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets, Clin Sci (Lond), 115, 203, 10.1042/CS20070430
Nag, 1980, Study of non-muscle cells of the adult mammalian heart: a fine structural analysis and distribution, Cytobios, 28, 41
Naga Prasad, 2000, Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy, J Biol Chem, 275, 4693, 10.1074/jbc.275.7.4693
Naga Prasad, 2001, Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by beta-adrenergic receptor kinase 1. A role in receptor sequestration, J Biol Chem, 276, 18953, 10.1074/jbc.M102376200
Nakagawa, 1988, Postnatal DNA synthesis in hearts of mice: autoradiographic and cytofluorometric investigations, Cardiovasc Res, 22, 575, 10.1093/cvr/22.8.575
Neer, 1995, Heterotrimeric G proteins: organizers of transmembrane signals, Cell, 80, 249, 10.1016/0092-8674(95)90407-7
Nelson, 1986, Effect of changing levels of physical activity on blood-pressure and haemodynamics in essential hypertension, Lancet, 2, 473, 10.1016/S0140-6736(86)90354-5
Neri Serneri, 2001, Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function, Circ Res, 88, 961, 10.1161/hh0901.089882
Neri Serneri, 2001, Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes, Circ Res, 89, 977, 10.1161/hh2301.100982
Neubauer, 2007, The failing heart—an engine out of fuel, N Engl J Med, 356, 1140, 10.1056/NEJMra063052
Nicol, 2001, Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy, EMBO J, 20, 2757, 10.1093/emboj/20.11.2757
Nienaber, 2003, Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure, J Clin Invest, 112, 1067, 10.1172/JCI18213
Nishida, 2004, p38{alpha} mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload, Mol Cell Biol, 24, 10611, 10.1128/MCB.24.24.10611-10620.2004
Nishida, 2008, Crosstalk between autophagy and apoptosis in heart disease, Circ Res, 103, 343, 10.1161/CIRCRESAHA.108.175448
Nishiyama, 1998, Effects of thyroid status on expression of voltage-gated potassium channels in rat left ventricle, Cardiovasc Res, 40, 343, 10.1016/S0008-6363(98)00135-7
Nunez, 1997, Retinoid X receptor and peroxisome proliferator-activated receptor activate an estrogen responsive gene independent of the estrogen receptor, Mol Cell Endocrinol, 127, 27, 10.1016/S0303-7207(96)03980-9
O'Connell, 2003, The alpha(1A/C)- and alpha(1B)-adrenergic receptors are required for physiological cardiac hypertrophy in the double-knockout mouse, J Clin Investig, 111, 1783, 10.1172/JCI200316100
O'Connell, 2006, Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload, J Clin Invest, 116, 1005, 10.1172/JCI22811
Okere, 2005, High-fat diet prevents cardiac hypertrophy and improves contractile function in the hypertensive dahl salt-sensitive rat, Clin Exp Pharmacol Physiol, 32, 825, 10.1111/j.1440-1681.2005.04272.x
Oliverio, 1998, Reduced growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II, Proc Natl Acad Sci U S A, 95, 15496, 10.1073/pnas.95.26.15496
Olivetti, 1995, Gender differences and aging: effects on the human heart, J Am Coll Cardiol, 26, 1068, 10.1016/0735-1097(95)00282-8
Olson, 2000, Calcineurin signaling and muscle remodeling, Cell, 101, 689, 10.1016/S0092-8674(00)80880-6
Orenstein, 1995, Favorable left ventricular remodeling following large myocardial infarction by exercise training. Effect on ventricular morphology and gene expression, J Clin Invest, 96, 858, 10.1172/JCI118132
Osadchii, 2007, Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease, Cardiovasc Drugs Ther, 21, 171, 10.1007/s10557-007-6014-6
Ostadal, 1999, Development of cardiac sensitivity to oxygen deficiency: comparative and ontogenetic aspects, Physiol Rev, 79, 635, 10.1152/physrev.1999.79.3.635
Oudit, 2007, Role of PI3 kinase gamma in excitation–contraction coupling and heart disease, Cardiovasc Hematol Disord Drug Targets, 7, 295, 10.2174/187152907782793545
Oudit, 2003, Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure, Circulation, 108, 2147, 10.1161/01.CIR.0000091403.62293.2B
Oudit, 2004, The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease, J Mol Cell Cardiol, 37, 449, 10.1016/j.yjmcc.2004.05.015
Owen, 2009, The protective effects of exercise and phosphoinositide 3-kinase (p110alpha) in the failing heart, Clin Sci (Lond), 116, 365, 10.1042/CS20080183
Packer, 2005, Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study, J Card Fail, 11, 12, 10.1016/j.cardfail.2004.05.006
Paradis, 2000, Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling, Proc Natl Acad Sci U S A, 97, 931, 10.1073/pnas.97.2.931
Park, 2007, Lipids in the heart: a source of fuel and a source of toxins, Curr Opin Lipidol, 18, 277, 10.1097/MOL.0b013e32814a57db
Parrizas, 1997, Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways, J Biol Chem, 272, 154, 10.1074/jbc.272.1.154
Pasumarthi, 2002, Cardiomyocyte cell cycle regulation, Circ Res, 90, 1044, 10.1161/01.RES.0000020201.44772.67
Patrucco, 2004, PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects, Cell, 118, 375, 10.1016/j.cell.2004.07.017
Patten, 2006, Estrogen replacement and cardiomyocyte protection, Trends Cardiovasc Med, 16, 69, 10.1016/j.tcm.2006.01.002
Payne, 1991, Identification of the regulatory phosphorylation sites in pp 42/mitogen-activated protein kinase (MAP kinase), EMBO J, 10, 885, 10.1002/j.1460-2075.1991.tb08021.x
Pearson, 2001, Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions, Endocr Rev, 22, 153, 10.1210/er.22.2.153
Pellegrini, 1997, The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs), Eur J Biochem, 248, 615, 10.1111/j.1432-1033.1997.00615.x
Pelzer, 2005, Increased mortality and aggravation of heart failure in estrogen receptor-beta knockout mice after myocardial infarction, Circulation, 111, 1492, 10.1161/01.CIR.0000159262.18512.46
Peng, 2006, Inactivation of focal adhesion kinase in cardiomyocytes promotes eccentric cardiac hypertrophy and fibrosis in mice, J Clin Invest, 116, 217, 10.1172/JCI24497
Perrino, 2005, Restoration of beta-adrenergic receptor signaling and contractile function in heart failure by disruption of the betaARK1/phosphoinositide 3-kinase complex, Circulation, 111, 2579, 10.1161/CIRCULATIONAHA.104.508796
Perrino, 2006, Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction, J Clin Invest, 116, 1547, 10.1172/JCI25397
Perrino, 2007, Dynamic regulation of phosphoinositide 3-kinase-gamma activity and beta-adrenergic receptor trafficking in end-stage human heart failure, Circulation, 116, 2571, 10.1161/CIRCULATIONAHA.107.706515
Petrich, 2004, Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies, Trends Cardiovasc Med, 14, 50, 10.1016/j.tcm.2003.11.002
Petrich, 2003, Temporal activation of c-Jun N-terminal kinase in adult transgenic heart via cre-loxP-mediated DNA recombination, FASEB J, 17, 749, 10.1096/fj.02-0438fje
Petrich, B.G., Eloff, B. C., Lerner, D. L., Kovacs, A., Saffitz, J. E., Rosenbaum, D. S., et al. (2004). Targeted activation of c-Jun N-terminal kinase in vivo induces restrictive cardiomyopathy and conduction defects. J Biol Chem 279(15), 15330–15338.
Pluim, 2000, The athlete's heart. A meta-analysis of cardiac structure and function, Circulation, 101, 336, 10.1161/01.CIR.101.3.336
Podesser, 2007, Unveiling gender differences in demand ischemia: a study in a rat model of genetic hypertension, Eur J Cardio-Thor Surg, 31, 298, 10.1016/j.ejcts.2006.10.041
Popescu, 2006, Insights into the interstitium of ventricular myocardium: interstitial Cajal-like cells (ICLC), J Cell Mol Med, 10, 429, 10.1111/j.1582-4934.2006.tb00410.x
Pracyk, 1998, A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy, J Clin Invest, 102, 929, 10.1172/JCI2552
Pretorius, 2008, Promoting physiological hypertrophy in the failing heart, Clin Exp Pharmacol Physiol, 35, 438, 10.1111/j.1440-1681.2008.04893.x
Pretorius, 2009, Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation, Am J Pathol, 175, 998, 10.2353/ajpath.2009.090126
Pretorius, 2009, Role of phosphoinositide 3-kinases in regulating cardiac function, Front Biosci, 14, 2221, 10.2741/3374
Pu, 2003, NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro, Circ Res, 92, 725, 10.1161/01.RES.0000069211.82346.46
Purcell, 2007, Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo, Proc Natl Acad Sci U S A, 104, 14074, 10.1073/pnas.0610906104
Raake, 2008, G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure, Circ Res, 103, 413, 10.1161/CIRCRESAHA.107.168336
Radak, 2008, Systemic adaptation to oxidative challenge induced by regular exercise, Free Radic Biol Med, 44, 153, 10.1016/j.freeradbiomed.2007.01.029
Ramirez, 1997, The MEKK-JNK pathway is stimulated by alpha1-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy, J Biol Chem, 272, 14057, 10.1074/jbc.272.22.14057
Ramirez, 1997, The nuclear deltaB isoform of Ca2+/calmodulin-dependent protein kinase II regulates atrial natriuretic factor gene expression in ventricular myocytes, J Biol Chem, 272, 31203, 10.1074/jbc.272.49.31203
Rao, 2009, Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure, Circ Res, 105, 585, 10.1161/CIRCRESAHA.109.200451
Rapacciuolo, 2001, Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy, J Am Coll Cardiol, 38, 876, 10.1016/S0735-1097(01)01433-4
Regitz-Zagrosek, V. (2006). Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nature Reviews. Drug Discovery 5(5), 425–438.
Reiss, 1996, Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice, Proc Natl Acad Sci U S A, 93, 8630, 10.1073/pnas.93.16.8630
Reisz-Porszasz, 2003, Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin, Am J Physiol Endocrinol Metab, 285, E876, 10.1152/ajpendo.00107.2003
Ren, 1999, Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease, J Mol Cell Cardiol, 31, 2049, 10.1006/jmcc.1999.1036
Ren, 2009, MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20, Circulation, 119, 2357, 10.1161/CIRCULATIONAHA.108.814145
Rich, 2003, Endothelin receptor blockers in cardiovascular disease, Circulation, 108, 2184, 10.1161/01.CIR.0000094397.19932.78
Rigor, 2009, Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase C{beta}2 in the regulation of physiologic developmental hypertrophy and heart function, Am J Physiol Heart Circ Physiol, 296, H566, 10.1152/ajpheart.00562.2008
Rimbaud, 2009, Stimulus specific changes of energy metabolism in hypertrophied heart, J Mol Cell Cardiol, 46, 952, 10.1016/j.yjmcc.2009.01.013
Rintelen, 2001, PDK1 regulates growth through Akt and S6K in Drosophila, Proc Nat Acad Sci U S A, 98, 15020, 10.1073/pnas.011318098
Robbins, 1993, Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro, J Biol Chem, 268, 5097, 10.1016/S0021-9258(18)53507-9
Robinson, 2009, Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease, Pharmacol Ther, 122, 246, 10.1016/j.pharmthera.2009.03.003
Rockman, 2002, Seven-transmembrane-spanning receptors and heart function, Nature, 415, 206, 10.1038/415206a
Rohrer, 1988, Thyroid hormone markedly increases the mRNA coding for sarcoplasmic reticulum Ca2+-ATPase in the rat heart, J Biol Chem, 263, 6941, 10.1016/S0021-9258(18)68584-9
Roman, 2001, PKC-beta is not necessary for cardiac hypertrophy, Am J Physiol Heart Circ Physiol, 280, H2264, 10.1152/ajpheart.2001.280.5.H2264
Rosen, 1990, Premature mortality due to cardiovascular disease in hypopituitarism, Lancet, 336, 285, 10.1016/0140-6736(90)91812-O
Rosenkranz, 2004, TGF-beta1 and angiotensin networking in cardiac remodeling, Cardiovasc Res, 63, 423, 10.1016/j.cardiores.2004.04.030
Rosenkranz, 2002, Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1), Am J Physiol Heart Circ Physiol, 283, H1253, 10.1152/ajpheart.00578.2001
Rothermel, 2001, Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo, Proc Natl Acad Sci U S A, 98, 3328, 10.1073/pnas.041614798
Ruan, 2009, Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury, J Mol Cell Cardiol, 46, 193, 10.1016/j.yjmcc.2008.10.021
Rupp, 1981, The adaptive changes in the isoenzyme pattern of myosin from hypertrophied rat myocardium as a result of pressure overload and physical training, Basic Res Cardiol, 76, 79, 10.1007/BF01908164
Sabri, 2003, Protein kinase C isoform-selective signals that lead to cardiac hypertrophy and the progression of heart failure, Mol Cell Biochem, 251, 97, 10.1023/A:1025490017780
Sack, 1997, A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program, Proc Natl Acad Sci U S A, 94, 6438, 10.1073/pnas.94.12.6438
Sadoshima, 1993, Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype, Circ Res, 73, 413, 10.1161/01.RES.73.3.413
Sadoshima, 1997, The cellular and molecular response of cardiac myocytes to mechanical stress, Annu Rev Physiol, 59, 551, 10.1146/annurev.physiol.59.1.551
Sadoshima, 1995, Angiotensin II and other hypertrophic stimuli mediated by G protein-coupled receptors activate tyrosine kinase, mitogen-activated protein kinase, and 90-kD S6 kinase in cardiac myocytes. The critical role of Ca(2+)-dependent signaling, Circ Res, 76, 1, 10.1161/01.RES.76.1.1
Sadoshima, 1996, The role of the cardiac renin–angiotensin system in load-induced cardiac hypertrophy, J Card Fail, 2, S1, 10.1016/S1071-9164(96)80052-2
Sadoshima, 2002, The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy, J Clin Invest, 110, 271, 10.1172/JCI0214938
Saito, 2000, beta-Adrenergic pathway induces apoptosis through calcineurin activation in cardiac myocytes, J Biol Chem, 275, 34528, 10.1074/jbc.M002844200
Saito, 2003, Roles of calcineurin and calcium/calmodulin-dependent protein kinase II in pressure overload-induced cardiac hypertrophy, J Mol Cell Cardiol, 35, 1153, 10.1016/S0022-2828(03)00234-7
Sakamoto, 2006, Upregulation of heat shock transcription factor 1 plays a critical role in adaptive cardiac hypertrophy, Circ Res, 99, 1411, 10.1161/01.RES.0000252345.80198.97
Salazar, 2007, Cardiac GPCRs: GPCR signaling in healthy and failing hearts, Biochim Biophys Acta, 1768, 1006, 10.1016/j.bbamem.2007.02.010
Salerno, 2004, Left ventricular mass and function in children with GH deficiency before and during 12months GH replacement therapy, Clin Endocrinol (Oxf), 60, 630, 10.1111/j.1365-2265.2004.02026.x
Sanger, 2000, Assembly of myofibrils in cardiac muscle cells, Adv Exp Med Biol, 481, 89, 10.1007/978-1-4615-4267-4_6
Sarkar, 2004, Influence of cytokines and growth factors in ANG II-mediated collagen upregulation by fibroblasts in rats: role of myocytes, Am J Physiol Heart Circ Physiol, 287, H107, 10.1152/ajpheart.00763.2003
Satomi-Kobayashi, 2009, Deficiency of nectin-2 leads to cardiac fibrosis and dysfunction under chronic pressure overload, Hypertension, 54, 825, 10.1161/HYPERTENSIONAHA.109.130443
Schaible, 1979, Effects of physical training by running or swimming on ventricular performance of rat hearts, J Appl Physiol, 46, 854, 10.1152/jappl.1979.46.4.854
Schaible, 1981, Cardiac function in hypertrophied hearts from chronically exercised female rats, J Appl Physiol, 50, 1140, 10.1152/jappl.1981.50.6.1140
Schaible, 1984, Response of the heart to exercise training
Schaible, 1986, Chronic swimming reverses cardiac dysfunction and myosin abnormalities in hypertensive rats, J Appl Physiol, 60, 1435, 10.1152/jappl.1986.60.4.1435
Scheinowitz, 2003, Short- and long-term swimming exercise training increases myocardial insulin-like growth factor-I gene expression, Growth Horm IGF Res, 13, 19, 10.1016/S1096-6374(02)00137-5
Scheuer, 1999, Catecholamines in cardiac hypertrophy, Am J Cardiol, 83, 70H, 10.1016/S0002-9149(99)00264-7
Scheuer, 1982, Physiologic cardiac hypertrophy corrects contractile protein abnormalities associated with pathologic hypertrophy in rats, J Clin Invest, 70, 1300, 10.1172/JCI110729
Schreiber, 2003, The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor alpha (ERRalpha), J Biol Chem, 278, 9013, 10.1074/jbc.M212923200
Schreiber, 2004, The estrogen-related receptor alpha (ERRalpha) functions in PPARgamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis, Proc Natl Acad Sci U S A, 101, 6472, 10.1073/pnas.0308686101
Schunkert, 1990, Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation, J Clin Invest, 86, 1913, 10.1172/JCI114924
Seed, 2001, Clinical experience with endothelin receptor antagonists in chronic heart failure, Heart Fail Rev, 6, 317, 10.1023/A:1011408425878
Seguchi, 2007, A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart, J Clin Invest, 117, 2812, 10.1172/JCI30804
Senbonmatsu, 2000, Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload, J Clin Invest, 106, R25, 10.1172/JCI10037
Shai, 2002, Cardiac myocyte-specific excision of the beta1 integrin gene results in myocardial fibrosis and cardiac failure, Circ Res, 90, 458, 10.1161/hh0402.105790
Sharma, 2004, Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart, FASEB J, 18, 1692, 10.1096/fj.04-2263com
Sheng, 1997, Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy, J Biol Chem, 272, 5783, 10.1074/jbc.272.9.5783
Shimoyama, 1999, Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy, Circulation, 100, 2449, 10.1161/01.CIR.100.24.2449
Shioi, 2000, The conserved phosphoinositide 3-kinase pathway determines heart size in mice, EMBO J, 19, 2537, 10.1093/emboj/19.11.2537
Shioi, 2002, Akt/protein kinase B promotes organ growth in transgenic mice, Mol Cell Biol, 22, 2799, 10.1128/MCB.22.8.2799-2809.2002
Shioi, 2003, Rapamycin attenuates load-induced cardiac hypertrophy in mice, Circulation, 107, 1664, 10.1161/01.CIR.0000057979.36322.88
Shiojima, 2005, Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure, J Clin Invest, 115, 2108, 10.1172/JCI24682
Shiraishi, 2004, Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes, Circ Res, 94, 884, 10.1161/01.RES.0000124394.01180.BE
Shubeita, 1990, Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy, J Biol Chem, 265, 20555, 10.1016/S0021-9258(17)30538-0
Shulman, 2003, Effects of one year of recombinant human growth hormone (GH) therapy on cardiac mass and function in children with classical GH deficiency, J Clin Endocrinol Metab, 88, 4095, 10.1210/jc.2003-030030
Simon, 1991, Diversity of G proteins in signal transduction, Science, 252, 802, 10.1126/science.1902986
Simoncini, 2000, Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase, Nature, 407, 538, 10.1038/35035131
Skavdahl, 2005, Estrogen receptor-beta mediates male–female differences in the development of pressure overload hypertrophy, Am J Physiol Heart Circ Physiol, 288, H469, 10.1152/ajpheart.00723.2004
Smeets, 2008, Cardiac hypertrophy is enhanced in PPAR alpha−/− mice in response to chronic pressure overload, Cardiovasc Res, 78, 79, 10.1093/cvr/cvn001
Solaro, 2008, Multiplex kinase signaling modifies cardiac function at the level of sarcomeric proteins, J Biol Chem, 283, 26829, 10.1074/jbc.R800037200
Son, 2007, Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice, J Clin Invest, 117, 2791, 10.1172/JCI30335
Soonpaa, 1996, Cardiomyocyte DNA synthesis and binucleation during murine development, Am J Physiol, 271, H2183
Sopontammarak, 2005, Mitogen-activated protein kinases (p38 and c-Jun NH2-terminal kinase) are differentially regulated during cardiac volume and pressure overload hypertrophy, Cell Biochem Biophys, 43, 61, 10.1385/CBB:43:1:061
Srinivasan, 1994, Alternative splicing introduces a nuclear localization signal that targets multifunctional CaM kinase to the nucleus, J Cell Biol, 126, 839, 10.1083/jcb.126.4.839
Strom, 2005, Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy, FEBS J, 272, 2684, 10.1111/j.1742-4658.2005.04684.x
Subramaniam, 1991, Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice, J Biol Chem, 266, 24613, 10.1016/S0021-9258(18)54273-3
Sugden, 2001, Signalling pathways in cardiac myocyte hypertrophy, Ann Med, 33, 611
Sullivan, 2003, Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis, Am Heart J, 145, 190, 10.1067/mhj.2003.142
Swedberg, 1979, Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade, Lancet, 1, 1374, 10.1016/S0140-6736(79)92010-5
Swedberg, 1980, Beneficial effects of long-term beta-blockade in congestive cardiomyopathy, Br Heart J, 44, 117, 10.1136/hrt.44.2.117
Swynghedauw, 1986, Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles, Physiol Rev, 66, 710, 10.1152/physrev.1986.66.3.710
Swynghedauw, 1999, Molecular mechanisms of myocardial remodeling, Physiol Rev, 79, 215, 10.1152/physrev.1999.79.1.215
Tachibana, 2006, JNK1 is required to preserve cardiac function in the early response to pressure overload, Biochem Biophys Res Commun, 343, 1060, 10.1016/j.bbrc.2006.03.065
Taigen, 2000, Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy, Proc Natl Acad Sci U S A, 97, 1196, 10.1073/pnas.97.3.1196
Takahashi, 2003, Deficit of CD38/cyclic ADP-ribose is differentially compensated in hearts by gender, Biochem Biophys Res Commun, 312, 434, 10.1016/j.bbrc.2003.10.143
Takahashi, 2007, Pressure overload-induced cardiomyopathy in heterozygous carrier mice of carnitine transporter gene mutation, Hypertension, 50, 497, 10.1161/HYPERTENSIONAHA.107.088609
Takeishi, 2000, Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy, Circ Res, 86, 1218, 10.1161/01.RES.86.12.1218
Takeishi, 2001, Src and multiple MAP kinase activation in cardiac hypertrophy and congestive heart failure under chronic pressure-overload: comparison with acute mechanical stretch, J Mol Cell Cardiol, 33, 1637, 10.1006/jmcc.2001.1427
Tamura, 1999, Gender-related differences in myocyte remodeling in progression to heart failure, Hypertension, 33, 676, 10.1161/01.HYP.33.2.676
Tang, 2009, MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2, Int Heart J, 50, 377, 10.1536/ihj.50.377
Tatsuguchi, 2007, Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy, J Mol Cell Cardiol, 42, 1137, 10.1016/j.yjmcc.2007.04.004
Tcherepanova, 2000, Modulation of estrogen receptor-alpha transcriptional activity by the coactivator PGC-1, J Biol Chem, 275, 16302, 10.1074/jbc.M001364200
Thom, 2006, Heart Disease and Stroke Statistics—2006 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, 113, e85, 10.1161/CIRCULATIONAHA.105.171600
Thomas, 2002, Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor, Circ Res, 90, 135, 10.1161/hh0202.104109
Thum, 2008, MicroRNAs: novel regulators in cardiac development and disease, Cardiovasc Res, 79, 562, 10.1093/cvr/cvn137
Thum, 2008, MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts, Nature, 456, 980, 10.1038/nature07511
Tobimatsu, 1989, Tissue-specific expression of four types of rat calmodulin-dependent protein kinase II mRNAs, J Biol Chem, 264, 17907, 10.1016/S0021-9258(19)84658-6
Toker, 1997, Signalling through the lipid products of phosphoinositide-3-OH kinase, Nature, 387, 673, 10.1038/42648
Tomlinson, 2001, Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group, Lancet, 357, 425, 10.1016/S0140-6736(00)04006-X
Traverse, 2006, Measurement of myocardial free radical production during exercise using EPR spectroscopy, Am J Physiol Heart Circ Physiol, 290, H2453, 10.1152/ajpheart.00412.2005
Trivedi, 2007, Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity, Nat Med, 13, 324, 10.1038/nm1552
Tsoutsman, 2008, Impact of multiple gene mutations in determining the severity of cardiomyopathy and heart failure, Clin Exp Pharmacol Physiol, 35, 1349, 10.1111/j.1440-1681.2008.05037.x
Tsujita, 2006, Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy, Proc Natl Acad Sci U S A, 103, 11946, 10.1073/pnas.0510138103
Tsutsui, 1993, Cytoskeletal role in the contractile dysfunction of hypertrophied myocardium, Science, 260, 682, 10.1126/science.8097594
Turgeon, 2004, Hormone therapy: physiological complexity belies therapeutic simplicity, Science, 304, 1269, 10.1126/science.1096725
Uozumi, 2001, gp130 plays a critical role in pressure overload-induced cardiac hypertrophy, J Biol Chem, 276, 23115, 10.1074/jbc.M100814200
van Bilsen, 2009, Metabolic remodelling of the failing heart: beneficial or detrimental?, Cardiovasc Res, 81, 420, 10.1093/cvr/cvn282
van der Vusse, 1992, Fatty acid homeostasis in the normoxic and ischemic heart, Physiol Rev, 72, 881, 10.1152/physrev.1992.72.4.881
van Eickels, 2001, 17beta-estradiol attenuates the development of pressure-overload hypertrophy, Circulation, 104, 1419, 10.1161/hc3601.095577
van Rooij, 2007, MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets, J Clin Invest, 117, 2369, 10.1172/JCI33099
van Rooij, 2006, A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure, Proc Natl Acad Sci U S A, 103, 18255, 10.1073/pnas.0608791103
Vanhaesebroeck, 1999, Signaling by distinct classes of phosphoinositide 3-kinases, Experiment Cell Res, 253, 239, 10.1006/excr.1999.4701
Vanhaesebroeck, 1997, Phosphoinositide 3-kinases: a conserved family of signal transducers, Trends Biochem Sci, 22, 267, 10.1016/S0968-0004(97)01061-X
Vanhaesebroeck, 2001, Synthesis and function of 3-phosphorylated inositol lipids, Annu Rev Biochem, 70, 535, 10.1146/annurev.biochem.70.1.535
Vasan, 2003, Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study, Ann Intern Med, 139, 642, 10.7326/0003-4819-139-8-200310210-00007
Vega, 2003, Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy, Proc Natl Acad Sci U S A, 100, 669, 10.1073/pnas.0237225100
Verdu, 1999, Cell-autonomous regulation of cell and organ growth in Drosophila by Akt/PKB, Nat Cell Biol, 1, 500, 10.1038/70293
Vigoreaux, 1994, The muscle Z band: lessons in stress management, J Muscle Res Cell Motil, 15, 237, 10.1007/BF00123477
Villarreal, 1992, Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen, Am J Physiol, 262, H1861
Waagstein, 1975, Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy, Br Heart J, 37, 1022, 10.1136/hrt.37.10.1022
Waagstein, 1989, Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol, Circulation, 80, 551, 10.1161/01.CIR.80.3.551
Waetzig, 2005, Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage, Trends Pharmacol Sci, 26, 455
Wakasaki, 1997, Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy, Proc Natl Acad Sci U S A, 94, 9320, 10.1073/pnas.94.17.9320
Wang, 2007, Mitogen-activated protein kinases in heart development and diseases, Circulation, 116, 1413, 10.1161/CIRCULATIONAHA.106.679589
Wang, 2002, Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes, Circ Res, 91, 821, 10.1161/01.RES.0000041029.97988.E9
Wang, 1998, Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family, J Biol Chem, 273, 2161, 10.1074/jbc.273.4.2161
Wang, 1998, Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells, J Biol Chem, 273, 5423, 10.1074/jbc.273.10.5423
Weber, 1997, Monitoring tissue repair and fibrosis from a distance, Circulation, 96, 2488
Weber, 1991, Pathological hypertrophy and cardiac interstitium. Fibrosis and renin–angiotensin–aldosterone system, Circulation, 83, 1849, 10.1161/01.CIR.83.6.1849
Weber, 1993, Myocardial fibrosis: functional significance and regulatory factors, Cardiovasc Res, 27, 341, 10.1093/cvr/27.3.341
Weinberg, 1999, Gender differences in molecular remodeling in pressure overload hypertrophy, J Am Coll Cardiol, 34, 264, 10.1016/S0735-1097(99)00165-5
Weiss, 2002, Thyroid hormone and cardiac function in mice deficient in thyroid hormone receptor-alpha or -beta: an echocardiograph study, Am J Physiol Endocrinol Metab, 283, E428, 10.1152/ajpendo.00019.2002
Welch, 2002, Cardiac-specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice, Circ Res, 90, 641, 10.1161/01.RES.0000013780.77774.75
Wencker, 2003, A mechanistic role for cardiac myocyte apoptosis in heart failure, J Clin Invest, 111, 1497, 10.1172/JCI17664
Wenger, 2002, Coronary heart disease and women: magnitude of the problem, Cardiol Rev, 10, 211, 10.1097/00045415-200207000-00005
Wettschureck, 2001, Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes, Nat Med, 7, 1236, 10.1038/nm1101-1236
Widmann, 1999, Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human, Physiol Rev, 79, 143, 10.1152/physrev.1999.79.1.143
Wikman-Coffelt, 1979, The cardiac hypertrophy process. Analyses of factors determining pathological vs. physiological development, Circ Res, 45, 697, 10.1161/01.RES.45.6.697
Wilkins, 2002, Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth, Mol Cell Biol, 22, 7603, 10.1128/MCB.22.21.7603-7613.2002
Wilkins, 2004, Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy, Circ Res, 94, 110, 10.1161/01.RES.0000109415.17511.18
Wilson, 1996, Crystal structure of p38 mitogen-activated protein kinase, J Biol Chem, 271, 27696, 10.1074/jbc.271.44.27696
Wollert, 1996, Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways, J Biol Chem, 271, 9535, 10.1074/jbc.271.16.9535
Woodcock, 2008, Cardiac alpha 1-adrenergic drive in pathological remodelling, Cardiovasc Res, 77, 452, 10.1093/cvr/cvm078
Woods, 2004, Cardioprotective functions of atrial natriuretic peptide and B-type natriuretic peptide: a brief review, Clin Exp Pharmacol Physiol, 31, 791, 10.1111/j.0305-1870.2004.04073.x
Wu, 2001, Increased myocardial Rab GTPase expression: a consequence and cause of cardiomyopathy, Circ Res, 89, 1130, 10.1161/hh2401.100427
Xin, 2002, Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy, Nature, 416, 334, 10.1038/416334a
Xu, 2003, Estrogen modulation of left ventricular remodeling in the aged heart, Cardiovasc Res, 57, 388, 10.1016/S0008-6363(02)00705-8
Yamamoto, 2003, Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy, J Clin Invest, 111, 1463, 10.1172/JCI17459
Yamazaki, 1997, Is there major involvement of the renin–angiotensin system in cardiac hypertrophy?, Circ Res, 81, 639
Yamazaki, 1993, Mechanical loading activates mitogen-activated protein kinase and S6 peptide kinase in cultured rat cardiac myocytes, J Biol Chem, 268, 12069, 10.1016/S0021-9258(19)50309-X
Yamazaki, 1999, Role of the renin–angiotensin system in cardiac hypertrophy, Am J Cardiol, 83, 53H, 10.1016/S0002-9149(99)00259-3
Yang, 2000, Decreased SLIM1 expression and increased gelsolin expression in failing human hearts measured by high-density oligonucleotide arrays, Circulation, 102, 3046, 10.1161/01.CIR.102.25.3046
Yayama, 2004, Up-regulation of angiotensin II type 2 receptor in rat thoracic aorta by pressure-overload, J Pharmacol Exp Ther, 308, 736, 10.1124/jpet.103.058420
Yeh, 1994, Effect of growth hormone administration and treadmill exercise on serum and skeletal IGF-I in rats, Am J Physiol, 266, E129
Zak, 1974, Development and proliferative capacity of cardiac muscle cells, Circ Res, 35, 17
Zak, R. (1984). Growth of the heart in health and disease. New York, Raven Press: 1–24, 131–185, 381–420
Zannad, 1999, Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidemiologie de l'Insuffisance Cardiaque Avancee en Lorraine, J Am Coll Cardiol, 33, 734, 10.1016/S0735-1097(98)00634-2
Zeisberg, 2007, Endothelial-to-mesenchymal transition contributes to cardiac fibrosis, Nat Med, 13, 952, 10.1038/nm1613
Zhai, 2007, Glycogen synthase kinase-3alpha reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases, J Biol Chem, 282, 33181, 10.1074/jbc.M705133200
Zhang, 2002, Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy, Cell, 110, 479, 10.1016/S0092-8674(02)00861-9
Zhang, 2002, The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity, J Biol Chem, 277, 1261, 10.1074/jbc.M108525200
Zhang, 2003, The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis, J Clin Invest, 111, 833, 10.1172/JCI16290
Zhang, 2003, The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure, Circ Res, 92, 912, 10.1161/01.RES.0000069686.31472.C5
Zhang, 2005, Calmodulin kinase II inhibition protects against structural heart disease, Nat Med, 11, 409, 10.1038/nm1215
Zhu, 1997, Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy, Am J Cardiol, 80, 110A, 10.1016/S0002-9149(97)00465-7
Zimmerman, 1997, Tissue renin–angiotensin system: a site of drug action?, Annu Rev Pharmacol Toxicol, 37, 53, 10.1146/annurev.pharmtox.37.1.53
Zipes, 2005